First Author, CNIO triple-therapy study; Co-founder, Vega Oncotargets
Appears in 1 story
Named in PNAS retraction for undisclosed financial stake in Vega Oncotargets; paper resubmitted through standard peer review
In April 2026, daraxonrasib became the first drug to beat chemotherapy in a Phase 3 pancreatic cancer trial, cutting death risk by 60% and extending median survival from 6.7 to 13.2 months. The FDA authorized expanded access May 1; Revolution Medicines plans to file a New Drug Application and present full Phase 3 data at the ASCO Annual Meeting on May 31, 2026.
Updated 5 days ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
